HealthDay News — US health officials are proposing a new way to develop and approve custom-made treatments for people with rare and hard-to-treat conditions.

The device is administered as a swallowable capsule that is filled with liquid by a physician and naturally leaves the body after approximately 4 months.

The FDA granted zongertinib Breakthrough Therapy Designation for patients with HER2 (ERBB2)-mutant advanced NSCLC as an initial treatment. The FDA also awarded a Commissioner's National Priority ...

Dusty Springfield passed away; Bo Diddley recorded his first single; the Four Seasons notched their third number-one hit; the ...

MPR News is tracking federal immigration actions across Minnesota — from U.S. Immigration and Customs Enforcement operations and policy changes to community impact and your rights. What to do if ICE ...

HERNEXEOS product image Product image This press release is not intended for UK media HERNEXEOS® (zongertinib tablets) ...

FDA approves swallowable Allurion Gastric Balloon for weight loss in adults with obesity who failed prior lifestyle programs.

This press release is not intended for UK media HERNEXEOS (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as demonstrated in the Beamion LUNG-1 clinical trial1 Acceler ...

Reports on the resignation of Kayode Egbetokun as the inspector-general of police (IGP) and the appointment of Tunji Disu as the acting IGP dominate the front pages of Nigerian newspapers.